# Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

> **NCT00731198** · PHASE3 · COMPLETED · sponsor: **Changhai Hospital** · enrollment: 650 (actual)

## Conditions studied

- ERCP
- Pancreatic Diseases
- Bile Duct Diseases

## Interventions

- **DRUG:** Drotaverine hydrochloride
- **DRUG:** Hyoscine-N-butylbromide

## Key facts

- **NCT ID:** NCT00731198
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-03
- **Final completion:** 2009-07
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2010-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731198, "Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00731198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*